[203Pb]VMT-α-NET + [212Pb]VMT-α-NET

Phase 1/2Recruiting

1 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neuroendocrine Tumors Unresectable

Conditions

Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma

Trial Timeline

Sep 27, 2023 → Dec 26, 2029

NCT ID

NCT05636618

About [203Pb]VMT-α-NET + [212Pb]VMT-α-NET

[203Pb]VMT-α-NET + [212Pb]VMT-α-NET is a phase 1/2 stage product being developed by Perspective Therapeutics for Neuroendocrine Tumors Unresectable. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05636618. Target conditions include Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor.

What happened to similar drugs?

6 of 16 similar drugs in Neuroendocrine Tumors Unresectable were approved

Approved (6) Terminated (2) Active (9)

✅Everolimus (RAD001)NovartisApproved

✅Pasireotide + DiazoxideNovartisApproved

✅everolimusNovartisApproved

✅sunitinibPfizerApproved

✅lanreotide acetateIpsenApproved

✅lanreotide (Autogel formulation)IpsenApproved

🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05636618	Phase 1/2	Recruiting	Sep 27, 2023	Dec 26, 2029	Neuroendocrine Tumors Unresectable

Competing Products

20 competing products in Neuroendocrine Tumors Unresectable

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	27
Lenvatinib	Eisai	Phase 2	35
Abemaciclib	Eli Lilly	Phase 2	39
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.	Jiangsu Hengrui Medicine	Phase 3	47
Famitinib	Jiangsu Hengrui Medicine	Phase 2	27
68Ga-DOTATOC	Jiangsu Hengrui Medicine	Phase 3	47
Olaparib	AstraZeneca	Phase 2	27
Avelumab	Merck	Phase 1/2	32
Pembrolizumab	Merck	Phase 2	27
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	35
Pembrolizumab Injection	Merck	Phase 2	27
Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab	Merck	Phase 1	33
Avelumab	Merck	Phase 2	35
Pembrolizumab + Lenvatinib	Merck	Phase 2	35
Avelumab	Merck	Phase 2	35
Pembrolizumab + Irinotecan + Paclitaxel	Merck	Phase 2	35
MK-0646	Merck	Phase 2	35
Lanreotide + Pembrolizumab	Merck	Phase 1/2	32